$RSPI
RespireRx Pharmaceuticals Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223029607 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $245.1K $367.6K $211.4K
YoY Change -2.31% 73.92% -50.4%
% of Gross Profit
Research & Development $87.38K $98.22K $141.1K
YoY Change -36.7% -30.39% -40.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $332.5K $465.9K $352.5K
YoY Change -14.51% 32.17% -46.92%
Operating Profit -$332.5K -$465.9K -$352.5K
YoY Change -14.51% 32.17% -46.92%
Interest Expense $73.41K $225.0K -$127.8K
YoY Change -689.62% -276.08% -13.76%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$395.5K -$681.0K -$480.3K
YoY Change -16.31% 41.8% -40.87%
Income Tax
% Of Pretax Income
Net Earnings -$395.5K -$681.0K -$480.3K
YoY Change -16.31% 41.8% -40.87%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 -$0.01
Diluted Earnings Per Share $0.00 $0.00 -$4.528K
COMMON SHARES
Basic Shares Outstanding 275.7M shares 144.3M shares 106.1M shares
Diluted Shares Outstanding 267.7M shares 168.2M shares 106.1M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.360K $7.320K $20.00
YoY Change 10500.0% 36500.0% -99.94%
Cash & Equivalents $6.362K $7.321K $21.00
Short-Term Investments
Other Short-Term Assets $102.3K $134.0K $77.69K
YoY Change 102.43% 72.42% -29.63%
Inventory
Prepaid Expenses $47.28K $77.19K $77.69K
Receivables
Other Receivables
Total Short-Term Assets $108.7K $141.3K $77.71K
YoY Change 114.74% 81.8% -45.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $108.7K $141.3K $77.71K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $108.7K $141.3K $77.71K
YoY Change 114.74% 81.8% -45.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.628M $5.890M $5.586M
YoY Change 15.24% 5.42% 8.71%
Accrued Expenses $2.652M $3.447M $2.969M
YoY Change -15.28% 16.09% 39.27%
Deferred Revenue
YoY Change
Short-Term Debt $2.781M $2.873M $2.420M
YoY Change 8.82% 18.75% 43.28%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.06M $12.21M $10.98M
YoY Change 5.45% 11.25% 22.5%
LONG-TERM LIABILITIES
Long-Term Debt $344.0K $74.00K $234.0K
YoY Change 68.63% -68.38%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $344.0K $74.00K $234.0K
YoY Change 68.63% -68.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.06M $12.21M $10.98M
Total Long-Term Liabilities $344.0K $74.00K $234.0K
Total Liabilities $12.41M $12.28M $11.21M
YoY Change 6.56% 9.59% 25.11%
SHAREHOLDERS EQUITY
Retained Earnings -$177.6M -$177.2M -$175.3M
YoY Change 1.02% 1.07%
Common Stock $298.3K $220.7K $117.1K
YoY Change 149.45% 88.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.30M -$12.14M -$11.13M
YoY Change
Total Liabilities & Shareholders Equity $108.7K $141.3K $77.71K
YoY Change 114.74% 81.8% -45.45%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$395.5K -$681.0K -$480.3K
YoY Change -16.31% 41.8% -40.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$101.0K -$128.6K -$61.99K
YoY Change 44.35% 107.42% -84.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 135.8K 61.76K
YoY Change 42.92% 119.82% -85.58%
NET CHANGE
Cash From Operating Activities -101.0K -128.6K -61.99K
Cash From Investing Activities
Cash From Financing Activities 100.0K 135.8K 61.76K
Net Change In Cash -960.0 7.180K -230.0
YoY Change -3300.0% -3221.74% -100.86%
FREE CASH FLOW
Cash From Operating Activities -$101.0K -$128.6K -$61.99K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000849636
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
usd
CY2022Q4 RSPI Prepaid Research And Development
PrepaidResearchAndDevelopment
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
usd
RSPI Proceeds From Sale Of Demand Promissory Notes
ProceedsFromSaleOfDemandPromissoryNotes
usd
RSPI Payment Of Fees Associated With Conversions Of Convertible Notes By Issuance Of Stock
PaymentOfFeesAssociatedWithConversionsOfConvertibleNotesByIssuanceOfStock
usd
RSPI Proceeds From Insurance Financings Net Of Repayments
ProceedsFromInsuranceFinancingsNetOfRepayments
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
RSPI Deferred Offering Costs Applied Against Equity Proceeds
DeferredOfferingCostsAppliedAgainstEquityProceeds
usd
us-gaap Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset
ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
usd
RSPI Accrued Compensation Accounts Payable And Other Liabilities Exchanged Or Settled For Equity
AccruedCompensationAccountsPayableAndOtherLiabilitiesExchangedOrSettledForEquity
usd
RSPI Cashless Warrant Exercises
CashlessWarrantExercises
usd
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-16467
dei Entity Registrant Name
EntityRegistrantName
RESPIRERX PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0303583
dei Entity Address Address Line1
EntityAddressAddressLine1
126 Valley Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite C
dei Entity Address City Or Town
EntityAddressCityOrTown
Glen Rock
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07452
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
444-4947
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Not applicable
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
275728647 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7321 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88 usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
6661 usd
CY2023Q2 RSPI Prepaid Research And Development
PrepaidResearchAndDevelopment
50105 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
77189 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
22693 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
141276 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22781 usd
CY2023Q2 us-gaap Assets
Assets
141276 usd
CY2022Q4 us-gaap Assets
Assets
22781 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5889542 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5724390 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3446608 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3296008 usd
CY2023Q2 RSPI Convertible Note Payable Current
ConvertibleNotePayableCurrent
1289854 usd
CY2022Q4 RSPI Convertible Note Payable Current
ConvertibleNotePayableCurrent
1258315 usd
CY2023Q2 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
60483 usd
CY2022Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
15847 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12209628 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11729101 usd
CY2023Q2 us-gaap Accounts Payable Interest Bearing Noncurrent
AccountsPayableInterestBearingNoncurrent
74000 usd
CY2022Q4 us-gaap Accounts Payable Interest Bearing Noncurrent
AccountsPayableInterestBearingNoncurrent
174000 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
74000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
174000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
12283628 usd
CY2022Q4 us-gaap Liabilities
Liabilities
11903101 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
220728647 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
220728647 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125544276 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125544276 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
220729 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125544 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164133404 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164030289 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177168949 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176057856 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12142352 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11880320 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141276 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22781 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
367644 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
211376 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
659562 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
707170 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98215 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141099 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
196640 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
262257 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
465859 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
352475 usd
us-gaap Operating Expenses
OperatingExpenses
856202 usd
us-gaap Operating Expenses
OperatingExpenses
969427 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-465859 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-352475 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-856202 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-969427 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
225049 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
179521 usd
us-gaap Interest Expense
InterestExpense
292321 usd
us-gaap Interest Expense
InterestExpense
439169 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9878 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
51708 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
37430 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
68145 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-681030 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-480288 usd
us-gaap Net Income Loss
NetIncomeLoss
-1111093 usd
us-gaap Net Income Loss
NetIncomeLoss
-1340451 usd
CY2023Q2 RSPI Dividends On Preferred Stock And Deemed Dividends Associated With Mostfavored Nation Provisions Of Convertible Notes
DividendsOnPreferredStockAndDeemedDividendsAssociatedWithMostfavoredNationProvisionsOfConvertibleNotes
-10761 usd
CY2022Q2 RSPI Dividends On Preferred Stock And Deemed Dividends Associated With Mostfavored Nation Provisions Of Convertible Notes
DividendsOnPreferredStockAndDeemedDividendsAssociatedWithMostfavoredNationProvisionsOfConvertibleNotes
-351738 usd
RSPI Dividends On Preferred Stock And Deemed Dividends Associated With Mostfavored Nation Provisions Of Convertible Notes
DividendsOnPreferredStockAndDeemedDividendsAssociatedWithMostfavoredNationProvisionsOfConvertibleNotes
-10761 usd
RSPI Dividends On Preferred Stock And Deemed Dividends Associated With Mostfavored Nation Provisions Of Convertible Notes
DividendsOnPreferredStockAndDeemedDividendsAssociatedWithMostfavoredNationProvisionsOfConvertibleNotes
-351738 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-691791 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-832026 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1121854 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1692189 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.004
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.008
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.008
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.007
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.007
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.017
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.017
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168213521 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168213521 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106081803 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106081803 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158402599 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158402599 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102010657 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102010657 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11880320 usd
CY2023Q1 RSPI Stock Issued During Period Value Issuance Of Common Stock Upon Cashless Warrant Exercise
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponCashlessWarrantExercise
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-430063 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-12310383 usd
CY2023Q2 RSPI Stock Issued During Period Value Preferred Stock
StockIssuedDuringPeriodValuePreferredStock
70000 usd
CY2023Q2 RSPI Stock Issued During Period Accrued Dividend Value Preferred Stock
StockIssuedDuringPeriodAccruedDividendValuePreferredStock
0 usd
CY2023Q2 RSPI Stock Issued During Period Value Preferred Stock One
StockIssuedDuringPeriodValuePreferredStockOne
570000 usd
CY2023Q2 RSPI Stock Issued During Period Accrued Dividend Value Preferred Stock One
StockIssuedDuringPeriodAccruedDividendValuePreferredStockOne
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
84061 usd
CY2023Q2 RSPI Stock Issued During Period Value Issuance Of Common Stock Upon Cashless Warrant Exercise
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponCashlessWarrantExercise
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
125000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-681030 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12142352 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10007758 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-860163 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10867921 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10867921 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
25000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
191750 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-480288 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-11131459 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-11131459 usd
us-gaap Net Income Loss
NetIncomeLoss
-1111093 usd
us-gaap Net Income Loss
NetIncomeLoss
-1340451 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11076 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
336728 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
37646 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
68145 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
6661 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-177883 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
104601 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-47619 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
205970 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
304382 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
360600 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
360100 usd
us-gaap Increase Decrease In Due From Affiliates Current
IncreaseDecreaseInDueFromAffiliatesCurrent
-340312 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
184276 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
96762 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157767 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85122 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
70000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
25000 usd
RSPI Proceeds From Sale Of Demand Promissory Notes
ProceedsFromSaleOfDemandPromissoryNotes
95000 usd
RSPI Payment Of Fees Associated With Conversions Of Convertible Notes By Issuance Of Stock
PaymentOfFeesAssociatedWithConversionsOfConvertibleNotesByIssuanceOfStock
1500 usd
RSPI Proceeds From Insurance Financings Net Of Repayments
ProceedsFromInsuranceFinancingsNetOfRepayments
-37752 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
94997 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83745 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7233 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1377 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1398 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7321 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21 usd
us-gaap Interest Paid Net
InterestPaidNet
4728 usd
us-gaap Interest Paid Net
InterestPaidNet
5657 usd
RSPI Deferred Offering Costs Applied Against Equity Proceeds
DeferredOfferingCostsAppliedAgainstEquityProceeds
11075 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
100000 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
60000 usd
us-gaap Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset
ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
25000 usd
RSPI Accrued Compensation Accounts Payable And Other Liabilities Exchanged Or Settled For Equity
AccruedCompensationAccountsPayableAndOtherLiabilitiesExchangedOrSettledForEquity
570000 usd
RSPI Debt And Accrued Interest Converted To Common Stock
DebtAndAccruedInterestConvertedToCommonStock
84060 usd
RSPI Debt And Accrued Interest Converted To Common Stock
DebtAndAccruedInterestConvertedToCommonStock
190250 usd
RSPI Cashless Warrant Exercises
CashlessWarrantExercises
39145 usd
CY2023Q2 RSPI Ordinary Shares
OrdinaryShares
25000000 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-681030 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-691791 usd
us-gaap Net Income Loss
NetIncomeLoss
-1111093 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1121854 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-480288 usd
us-gaap Net Income Loss
NetIncomeLoss
-1340451 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-832026 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1692189 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3972993 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157767 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-143905 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12142352 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1289854 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zqdW6dwGpTgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zPPthrYLCtCf">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z3OmDs0L9mjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zvTixmsVt6sg">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
2212500 shares
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired
0.0160
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
93310598 shares
CY2022Q2 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0472
RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P2Y6M20D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2022Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2023Q2 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
83333333 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0038
us-gaap Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend
IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
<p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_z1yMEYrjqhhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zyMg9SQC66Nd">Patent Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1123343728 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
186231560 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zNuOfysdhkyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zk0awFuLiGA1">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Interest Paid
InterestPaid
2404 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0015
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Dividends
Dividends
9870 usd
CY2023Q2 RSPI Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3485924 shares
CY2022Q4 RSPI Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3504424 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
220728647 shares
us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
56039999 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
642219502 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
419683183 shares
CY2022Q4 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0074
CY2022 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
49800000 shares
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised
0.0015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
83333333 shares
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued
0.0015
RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued
P4Y10M24D
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired
-23881 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
453192635 shares
CY2023Q2 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0060
RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M7D
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0015
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
59420298 shares
CY2021Q4 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0718
CY2021 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
36102800 shares
RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued
0.0100
RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued
P4Y3M17D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9199356 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.592
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M26D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
31039 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.200
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9168317 shares
CY2023Q2 RSPI Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
0.556
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y9M
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
9168317 shares
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
9168317 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
220728647 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
220728647 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
453192635 shares
us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The features and terms of the Phantom Stock are delineated in Phantom Stock Award Agreements (“Phantom Stock Award Agreements”) which describe that the shares of Phantom Stock that were awarded are non-forfeitable but unvested on the award date which was June 7, 2023 and vest as to the economic value of 50% of the shares of Phantom Stock awarded on the first event payment date (“First Event Payment Date”) and as to the economic value of 50% of the shares of Phantom Stock awarded on the second event payment date (“Second Event Payment Date”)
RSPI Payment Of Fair Market Value Description
PaymentOfFairMarketValueDescription
If the calculation of the payment based on the definition of Fair Market Value, exceeds 50% the amount of cash received by RespireRx with respect to a Payment Event, an initial payment shall be limited to 50% of the cash received by RespireRx with respect to the Payment Event and the unpaid balance shall be carried as a liability due to the Participant to be added to the payment amount of the Second Payment Event, subject to the same limitation.
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
75000 usd
CY2021 RSPI Accounts Payable And Accrued Expenses
AccountsPayableAndAccruedExpenses
0 usd
RSPI Commercial Sale Of Product
CommercialSaleOfProduct
350000 usd
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
255485 usd
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
255485 usd
CY2023Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
200485 usd
CY2023Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
10000 usd
CY2023Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
15000 usd
CY2023Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
15000 usd
CY2023Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
15.0000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-23-029607-index-headers.html Edgar Link pending
0001493152-23-029607-index.html Edgar Link pending
0001493152-23-029607.txt Edgar Link pending
0001493152-23-029607-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rspi-20230630.xsd Edgar Link pending
form10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending
rspi-20230630_cal.xml Edgar Link unprocessable
rspi-20230630_lab.xml Edgar Link unprocessable
rspi-20230630_def.xml Edgar Link unprocessable
rspi-20230630_pre.xml Edgar Link unprocessable